Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Connecticut for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Connecticut only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Connecticut (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Kristina Bikoulova (NPI 1568119667)

Field	Value
Entity Type	Individual
Organization	Kristina Bikoulova
Address	249 Danbury Rd
City	Wilton
State	CT
ZIP	06897
Taxonomy	Family Nurse Practitioner
NPI Enumerated	March 8, 2022

Payer Source	Total Paid
Medicare	$1.9M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused practice with Total Medicare revenue of $1.9M and Medicaid revenue listed as none; there is no Medicaid billing on file so analyses of payer mix and state-program exposure should treat this entity as single‑payer Medicare in practice. The provider's NPI was enumerated 2022-03-08 (~4 years ago), indicating these billing patterns have emerged within a relatively short, recent tenure.

Revenue is highly concentrated: the precomputed top-3 Medicare codes account for 94.0% of her total Medicare revenue. The three lead codes are J3245 ($1.1M, 55.6%), J3380 ($637.5K, 33.6%), and J1745 ($90.7K, 4.8%), so the business is overwhelmingly driven by a narrow set of biologic drug codes rather than broad primary-care or procedure volume.

Clinical and service-line mix is consistent with an infusion/injectable biologics practice: the top revenue codes are J3245 (tildrakizumab), J3380 (vedolizumab), and J1745 (infliximab), and the presence of infusion administration codes such as 96365 (389 claims, $47 avg paid, $18.3K revenue) and 96366 indicates on-site IV administration capacity. These code descriptions and the claim volumes suggest the operation focuses on parenteral biologic therapy delivery rather than office-based evaluation-and-management or broad chronic disease management.

Competitive standing on key biologics is strong nationally: J3245 ranks #15 of 225 providers (94th percentile; notably above typical national volume) and J3380 ranks #18 of 620 providers (97th percentile; notably above typical national volume), signaling that this provider is a major national participant for those specific drugs. By contrast, J1745 ranks #576 of 1352 (57th percentile; typical, unremarkable volume), so the provider is not a top national outlier across all infusion biologics but is especially prominent for J3245 and J3380.

Several secondary codes also show above-typical national activity and corroborate an infusion-focused practice: J3489 (zoledronic acid) reports 395 claims and ranks in the 96th percentile (notably above typical national volume), and 96372 (subcutaneous/intramuscular injections) reports 492 claims and ranks in the 97th percentile (notably above typical national volume). However, these services represent small shares of total revenue (for example, J3489 revenue $2.8K and 96372 revenue $4.9K), underscoring that drug administration is common but drug units (J3245/J3380) drive dollars.

Operational exposure is concentrated in access to and reimbursement for a few high-cost biologics. Because J3245 and J3380 together represent the majority of Medicare dollars for this provider, changes in coverage policy, reimbursement rates, formulary placement, or supply for those drugs could materially affect revenue; conversely, the concentrated code mix could give payers targeted leverage in negotiation or utilization management focused on those agents.

Although the practice bills chemotherapy/infusion administration codes (96413, 96415 and related 9636x series), these appear as modest revenue contributors (for example, 96413 is $11.9K or 0.6% of revenue and 96415 is $2.8K or 0.1%). That pattern indicates the primary revenue driver is the drug itself rather than lengthy chemotherapy administration sessions: drug-unit J‑codes dominate payer spend for this provider.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

13 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3245	Injection, tildrakizumab, 1 mg	9,600	$110	$1.1M
J3380	Injection, vedolizumab, intravenous, 1 mg	37,500	$20	$637.5K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	3,490	$30	$90.7K
J0897	Injection, denosumab, 1 mg	3,900	$20	$70.2K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	390	$50	$18.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	130	$100	$11.9K
96372	A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician…	490	$10	$4.9K
96415	In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the…	140	$20	$2.8K
J3489	Injection, zoledronic acid, 1 mg	400	$10	$2.8K
96366	The provider administers an intravenous infusion or infusions of a medication for an additional hour or subsequent hours after the first hour to prevent, treat, or diagnose a condition or disease.	180	$20	$2.6K

Showing 1–10 of 13

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 13 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Connecticut Distribution

Kristina Bikoulova — 6 of 13 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Connecticut

Full comparison — all codes billed, vs. state median

13 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3245	1	10	5,500	$110	$605.3K
J3380	1	20	8,700	$20	$195.6K
J0897	31	100	2,700	$20	$66.4K
J1745	3	10	2,140	$30	$63.7K
96413	23	50	110	$110	$13.6K
96365	3	60	50	$50	$4.7K
96367	20	20	60	$20	$3.2K
96375	18	20	130	$10	$2.1K
96415	2	30	70	$20	$1.5K
96366	2	20	60	$20	$1.4K

Showing 1–10 of 13

Related Providers

Other providers that share a Tax Identification Number (TIN) with Kristina Bikoulova, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mariem Abedullah	NJ	Family Nurse Practitioner	$672.2K	$0
Melissa Robinson	NY	Family Nurse Practitioner	$354.5K	$0
Tracey Velo	CT	Family Nurse Practitioner	$330.5K	$0
Jeeness Macatangay	NY	Adult Health Nurse Practitioner	$274.7K	$0
Emily Dasilva	CT	Acute Care Nurse Practitioner	$158.9K	$0
Michelle Levins	NY	Registered Nurse	$70.4K	$5.2K

Nearby Providers

Other providers in the same ZIP code as Kristina Bikoulova, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Connec-totalk,llc	CT	Speech-Language Pathologist	$0	$6.1M
Wilton Surgery Center LLC	CT	Ambulatory Surgical Clinic/Center	$1.8M	$405.1K
Wilton Volunteer Ambulance Corps Inc	CT	Land Ambulance	$245.4K	$131K
Mark Fletcher	CT	Orthopaedic Surgery Physician	$268.8K	$0
Connecticut Cvs Pharmacy, L.L.C.	CT	Pharmacy	$184.7K	$0
Jeffrey Deluca	CT	Orthopaedic Surgery Physician	$182.8K	$0
Southwest Connecticut Surgery Center, LLC	CT	Ambulatory Surgical Clinic/Center	$154.8K	$0
Robert Brady	CT	Orthopaedic Surgery Physician	$153.8K	$0
Paul Protomastro	CT	Orthopaedic Hand Surgery Physician	$131.1K	$0
Charles Ma	CT	Endocrinology, Diabetes & Metabolism Physician	$130K	$0

Kristina Bikoulova — Billing Profile & Reimbursement Data

Sign up for Kristina Bikoulova — Billing Profile & Reimbursement Data policy alerts

Kristina Bikoulova — Billing Profile & Reimbursement Data

Sign up for Kristina Bikoulova — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References